Showing papers in "Clinical Breast Cancer in 2020"

TL;DR: High rates of anxiety, depression, distress, and insomnia were observed in patients with breast cancer during the COVID-19 outbreak, and special attention should be paid to psychological status of breast cancer patients especially those with poor general condition, treatment discontinuation, aggressive molecular subtypes and metastatic breast cancer.

TL;DR: The temporary halt of the national screening program for breast cancer in the Netherlands has resulted in fewer surgical procedures over time and a pronounced decrease in the lower tumor stages that were operated on.

TL;DR: In patients with nonmetastatic breast cancer, screening for asymptomatic brain metastases cannot currently be justified, however, due to the high incidence of brain metastased among patients with metastatic HER2+ and triple-negative breast cancers, studies to determine the value of screening for brain metastase should be undertaken in these subgroups.

TL;DR: RT combined with pembrolizumab did not produce an objective response in patients with heavily pre-treated HR+ MBC, and future studies should consider alternative radiation dosing and fractionation in Patients with less heavilyPre- treated HR+MBC.

TL;DR: The results are encouraging and suggest that this approach may prove useful for classifying lymph node status on MRI in clinical settings in patients with breast cancer, although additional studies are needed before routine clinical use can be realized.

TL;DR: The BPSS app is a feasible tool for patients with breast cancer and might be useful as a support tool for information sharing between patients and medical staff in an effort to optimize chemotherapy and deliver suitable patient care and support.

TL;DR: The results show meaningful activity of T-DM1 after front-line pertuzumab plus trastuzumAB and a taxane, with about 27% of patients having an objective response and 40% of Patients achieving durable disease control.

TL;DR: The history of BSE and CBE is reviewed and their value as early detection methods can contribute to informed decision-making by health policy-makers and clinicians who are involved in breast cancer screening in the developing world to improve women's well-being.

TL;DR: The present review explored the latest developments in the association of deregulation in the Wnt/β-catenin signal cascade with the pathogenesis of breast cancer, the progress in identifying the potential chemotherapeutic drugs inhibiting this pathway, and the status of these compounds in clinical trials of Breast cancer.

TL;DR: Spindle cell carcinomas are characterized by targetable molecular alterations in the majority of cases, but owing to the lack of uniform findings, individual patient profiling is necessary.

TL;DR: Real-world first-line palbociclib treatment produced outcomes similar to those in PALOMA-2 (PalbocIClib and Letrozole in Advanced Breast Cancer) (median PFS 26.4 months vs. 24.8 months) despite more dose reductions and shorter time to first dose reduction.

TL;DR: In patients with TNBC, AR expression is not associated with prognosis, regardless of confounding factors and heterogeneity that existed among included studies.

TL;DR: The presence of PIK3CA mutations may be associated with worse clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, and clinical outcomes may be improved using a combination of PI3Ki-based therapies and endocrine therapies among this population.

TL;DR: A systematic search of the reported data and a meta-analysis of prospective case-control and cohort studies indicated that a high intake of folate, vitamin B6, and vitamin B2 might decrease the risk of breast cancer.

TL;DR: Both biomarkers were associated with poor prognosis characteristics and with tumor infiltrating lymphocyte density and Chemokines can be associated with breast cancer subtype and outcome.

TL;DR: MiR-4472 contributes to the progression of breast cancer by regulating RGMA expression and inducing epithelial-to-mesenchymal transition, indicating that miR- 4472/RGMA might serve as a therapeutic target for breast cancer.

TL;DR: A modest increase in the rates of grade 3 or higher AEs after combined RT and CDK4/6i, with maintained efficacy of concomitant RT is observed.

TL;DR: Clinopathologic features may help predict HER2+ breast cancer response to neoadjuvant therapy, and larger studies would be useful to confirm these associations, which may have relevance to clinical practice.

TL;DR: Palbociclib + letrozole provided significant clinical benefit to patients with ER+/HER2- ABC regardless of achieving RECIST-defined OR, and among the patients with OR during the study, approximately 50% achieved OR within the first 3 months regardless of treatment.

TL;DR: BCS was associated with a greater rate of ipsilateral breast cancer recurrence in BRCA mutation carriers, however, it was not associated with adverse short- and long-term survival outcomes and should be offered as an option to BRCa mutation carriers with proper preoperative counseling.

TL;DR: The state of the art in the area of aberrant cfDNA methylation analyses as a diagnostic and prognostic tool in breast cancer is updated, the main technological challenges are reported, and an outlook for advancing the overall management of breast malignancies based on cfDNA as a target for diagnosis and tailored therapies is provided.

TL;DR: CircCDYL promotes apoptosis and inhibits proliferation of the malignant phenotype of breast cancer through regulating miR-190a-3p/TP53INP1 axis, which suggests that circCDYL is a potential therapeutic target for breast cancer.

TL;DR: Erlotinib and metformin were well tolerated in a population of pretreated mTNBC patients but did not demonstrate efficacy in this population.

TL;DR: The factors influencing mammographic density, the available methods of MD assessment, and its effect on breast cancer are reviewed.

TL;DR: mSMI is equal to CEUS and superior to CDFI and PDI in identifying microvascular and discriminating malignant and benign breast masses and the sensitivity, negative predictive value, and accuracy of mSMI findings in diagnosing malignancy based on PVs and vascular patterns were both higher than those of CDFI or PDI.

TL;DR: Different methods of immediate breast reconstruction post-mastectomy are feasible and safe, however, patient variables and procedure choice should be taken into consideration when counseling patients on reconstructive options, as they are strong predictors for postoperative complications.

TL;DR: Neratinib resulted in expected rates of diarrhea in this small cohort, with 2 of 5 patients receiving the study treatment for durable periods, although logistically challenging, the study was able to test a limited number of CSF- and parenchymal-based neratinib concentrations.

TL;DR: A roundtable meeting of the Breast Cancer Therapy Expert Group was convened in March 2018 in an effort to discuss and clarify, from the perspective of the practicing community oncologist, recent developments in the diagnosis and treatment of HER2-positive (HER2+) breast cancer.

TL;DR: Tumor biopsy with genomic sequencing and repeat biomarker analysis in patients with CDK4/6i- and endocrine-resistant disease will be integral to guide subsequent treatment strategies and to inform clinical trial eligibility.

TL;DR: This meta-analysis provides supporting evidence for the association between MD decreased risk of IDC and ILC of the breast and the link between WD and increased risk ofIDC andILC.